| A1 publicaties (5) [show] |
- Schoffski, P.; Dumez, H.; Ruijter, R.; Miguel-Lillo, B.; Soto-Matos, A.; Alfaro, V.; Giaccone, G. (2011). Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. Cancer Chemother. Pharmacol. 68(6): 1397-1403. dx.doi.org/10.1007/s00280-011-1612-1, meer
 Dumez, H.; Gallardo, E.; Culine, S.; Galceran, J.C.; Schöffski, P.; Droz, J.P.; Extremera, S.; Szyldergemajn, S.; Fléchon, A. (2009). Phase II study of biweekly Plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar. Drugs 7(3): 451-463. https://dx.doi.org/10.3390/md7030451, meer- Schöffski, P.; Guillem, V.; Garcia, M.; Rivera, F.; Tabernero, J.; Cullell, M.; Lopez-Martin, J.A.; Pollard, P.; Dumez, H.; del Muro, X.; Paz-Ares, L. (2009). Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar. Drugs 7(1): 57-70. https://dx.doi.org/10.3390/md7010057, meer
- Schöffski, P.; Dumez, H.; Wolter, P.; Stefan, C.; Wozniak, A.; Jimeno, J.; Van Oosterom, A.T. (2008). Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opinion on Pharmacotherapy 9(9): 1609-1618. https://dx.doi.org/10.1517/14656566.9.9.1609, meer
- Schöffski, P.; Grunwald, V.; Giaccone, G.; Salazar, R.; Majem, M.; Dumez, H.; Casado, E.; de las Heras, B.; Armand, J. (2008). Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors. European journal of cancer. Supplement (1990) 6(12): 56-56. dx.doi.org/10.1016/S1359-6349(08)72108-6, meer
|
|
